Compare ASYS & FULC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ASYS | FULC |
|---|---|---|
| Founded | 1981 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 312.2M | 285.4M |
| IPO Year | 2006 | 2019 |
| Metric | ASYS | FULC |
|---|---|---|
| Price | $16.47 | $3.78 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 2 | 5 |
| Target Price | ★ $22.50 | $3.67 |
| AVG Volume (30 Days) | 213.7K | ★ 1.2M |
| Earning Date | 08-05-2026 | 10-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.19 | N/A |
| Revenue | ★ $79,364,000.00 | N/A |
| Revenue This Year | $8.11 | N/A |
| Revenue Next Year | $39.86 | N/A |
| P/E Ratio | $85.32 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $6.75 | $2.83 |
| 52 Week High | $25.71 | $15.74 |
| Indicator | ASYS | FULC |
|---|---|---|
| Relative Strength Index (RSI) | 53.16 | 51.35 |
| Support Level | $15.89 | $3.75 |
| Resistance Level | $17.57 | $3.91 |
| Average True Range (ATR) | 0.63 | 0.07 |
| MACD | 0.09 | 0.00 |
| Stochastic Oscillator | 49.00 | 52.50 |
Amtech Systems Inc provides equipment, consumables and services for semiconductor device packaging, wafer production and device fabrication. Its products are used to fabricate and package GPUs for AI applications, SiC and Si power devices, and other optical, analog and digital devices, and are sold to semiconductor packaging, electronic assembly and device fabrication companies. It operates through two segments: Thermal Processing Solutions, which includes conveyorized reflow equipment, high-temperature conveyorized furnaces and diffusion furnaces with maximum revenue; and Semiconductor Fabrication Solutions, which includes consumables, equipment and services for wafer polishing, dicing and cleaning. The majority of revenue is derived from the United States.
Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing small molecules for genetically defined rare diseases. Its product candidate, Pociredir, is an oral small molecule designed to induce fetal hemoglobin (HbF) and is in clinical development for sickle cell disease (SCD). The company completed dosing in the Phase 1b PIONEER trial evaluating pociredir in adults with SCD and reported clinical data showing clinically relevant HbF induction and improvements in markers of hemolysis and anemia. The company has also generated a pipeline of clinical-stage and pre-clinical programs targeting the root causes of rare genetic diseases.